Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant paclitaxel-carboplatin versus observation in node-negative intermediate/high-risk stage I-II endometrial cancer
NL-OMON41312Phase 3Recruiting
- Sponsor
- Danish Gynecological Cancer Group
- Start
- Sep 2016
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel and carboplatin in endometrial cancer (EC) and uterine cancer (2 arms), sponsored by Danish Gynecological Cancer Group. Primary endpoint: Overall survival. Started Sep 2016; status: recruiting.
02
Drugs
paclitaxelcarboplatin
03
Conditions
endometrial cancer (EC)uterine cancer
Beyond the preview
Go deeper on NL-OMON41312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41312.